G. Budde

Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios

Omar H. Butt, G. Ansstas, A. Zhou, 2022, Frontiers in Oncology.

The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant

A. Aleshin, A. Poklepovic, A. Kasi, 2022, Case reports in obstetrics and gynecology.

Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers

M. Malhotra, D. Catenacci, P. Kasi, 2022, JCO precision oncology.

1415P Performance of a tumor-informed circulating tumor DNA assay from over 250 patients with over 600 plasma time points in esophageal and gastric cancer

P. Kasi, B. Huffman, S. Klempner, 2021, Annals of Oncology.

Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer

M. Malhotra, P. Kasi, Michael Krainock, 2022, Journal for ImmunoTherapy of Cancer.

Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma

T. Bowles, K. Boucher, R. Rathore, 2023, Melanoma research.

Tumor-informed assessment of circulating tumor DNA and its incorporation into practice for patients with hepatobiliary cancers.

M. Abdelrahim, M. Tejani, P. Kasi, 2021 .